THU0459 EXPLORING DUAL MODULATION OF GLUT9 AND OAT3, AN APICAL AND BASOLATERAL TRANSPORTERS IN PROXIMAL TUBULES AND EXPERIMENTAL MICE
S.H. Lee, S.B. Kim, D.-S. Oh. The K-herb Research Centre, Korea Institute of Oriental Medicine, Daejeon, Korea, Republic Of Background: Uric acid homeostasis is a set of the balance in glomerular filtration, tubular secretion, reabsorption, and excretion. In the course of cascade, two kinds play a pivotal role; efflux transporters in apical at renal proximal tubular membrane, uptake ones in basolateral at membrane. The former has been of interest in the targets for uricosuric effects, however, dual modulation of the two could keep uric acid balance in stable ways. Objectives: The aim of this study was to assess the uptake of seven test articles in the course of the expressions of apical/basolateral transporters in potassium oxonate (PO)-treated kidney epithelial cell lines (Caco-2, MDCK, LLC-PK1) and ICR mice. Methods: The selected cell lines were treated with potassium oxonate (0.25 mM) and then modulated by seven test articles, the commercial herbal products (SITK01 through SITK06 and SITT01) at dose range of 0.015-1 mg/mL. To determine efficacious dose range by each test article, three cell lines, Caco-2, MDCK and LLC-PK1 cells were assessed with MTT assay. Forty eight ICR mice were injected intraperitoneally with PO at a dose of 200 and 400 mg/kg and then blood draws were conducted 0, 6, 12, 24, 72 hours after PO administration. The levels of uric acid and transporters were also measured by ELISA assay and Western blotting analysis in those cell lines.
Results: Treatment of SITK01 through SITK03 and SITT01 at concentration (250 mg/mL) decreased the cell viability. The PO-stimulated kidney epithelial cells with SITK01 through SITK03 treatment increased GLUT9 by 2.5 folds and decreased OAT3 by 1.5 folds (versus controls, p=0.012, and p=0.017, respectively) . In PO-treated mice, uric acid levels were increased through GLUT9 and OAT3 transporters. The results indicated that SITK01, SITK02, and SITK03 showed the potential on uricosuric effects in a dual modulation of apical/basolateral sides of kidney epithelial tubular membranes. Background: Despite gout's well-known pathogenesis and the availability of effective urate-lowering therapy (ULT), management remains poor. However, limited research has sought to improve care among this patient population. An in-depth understanding of provider and patient perspectives on barriers to the delivery of optimal gout care is critical to informing the development of evidence-based interventions to effectively improve disease management and patient outcomes. Objectives: To systematically review and thematically synthesize qualitative studies to date reporting provider and patient barriers to gout management. Methods: We conducted a mapped search of MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, and Social Sciences Citation Index databases and selected qualitative studies reporting provider and patient perspectives on gout management. Thematic synthesis was used to combine the source studies and identify key themes across studies. Two authors independently read and annotated the data and after discussion agreed on an initial coding framework. Concepts were organized into descriptive themes, and the relationships between these descriptive themes were further explored to develop higher-order analytical themes. Results: Our search strategy retrieved 2,750 articles after the removal of duplicates. After full-text review, 20 studies spanning several geographic settings worldwide (i.e., the US, the UK, New Zealand, Australia, and the Netherlands) met all inclusion criteria and were included in our systematic review. Of these, 16 studies reported gout patient perspectives (n=480 patients), while only 7 studies reported provider perspectives (n=120 providers, including general practitioners, rheumatologists and other specialists, and allied health professionals). Thematic synthesis identified three predominant interlocking analytical themes among providers: (a) knowledge gaps and management approaches, (b) perceptions and beliefs about gout patients, and (c) system barriers to optimal gout care ( Table 1) . We further identified four predominant themes among gout patients: (a) limited gout knowledge (e.g., the "curable" nature of gout), (b) attitudes toward taking medication, (c) interactions with healthcare providers, and (d) practical barriers to chronic medication use (Table 1) .
